Kura Oncology (KURA)
(Delayed Data from NSDQ)
$20.61 USD
-0.08 (-0.39%)
Updated May 31, 2024 04:00 PM ET
After-Market: $20.63 +0.02 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 161 - 180 ( 257 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Nice Morning Feather in the Kura Cap; Keen Focus on KO-539; Target to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Early Targeting Win in Very Tough Group for KO-539; Target Upped to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Early KOMET Data Validates Broad AML Development Plan
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Acute Myeloid Leukemia: Current Treatment and Therapies in Development
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Results; Anticipation Mounts for ASH; First Look Points in Right Direction for KO-539
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Programs Expanding with New Cohorts for KO-539 and Tipi Planned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Look to Sky for a Nice View of a KOMET at ASH; Increasing PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Initial Menin Program Data at ASH; Tipifarnib Combo Planned
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Focus Is the Name of the Game for Kura
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Impressive Median Overall Survival for Tipifarnib in HRAS-HNSCC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R